et al.. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
INTRODUCTION

MATERIALS AND METHODS
Cell culture
Human prostate cancer cell lines LNCaP (clone FGC), 22Rv1, and DU145 were obtained from American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI 1640 supplemented with 10 FBS and penicillin/streptomycin. For this study low % passage cells were used (<20 passages). The LNCaP-AI variant (passage 16 to 20) was derived from LNCaP cultures maintained more than 18 months growth in androgen depleted medium (phenol red-free RPMI supplemented with 10 charcoal-stripped FBS). LNCaP and % 22Rv1 were authenticated through cell morphology monitoring, response to androgen treatment, and expression of Androgen Receptor which harbor mutations in these lines ( ). DU145 was authenticated by lack of AR expression, expression of mutant TP53 ( ), and 22 -24 24
assessment of the invasive behavior using Boyden chamber assays.
Western blot analysis
Protein lysates were prepared in the RIPA buffer (radioimmunoprecipitation assay lysis buffer) supplemented with protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) and phosphatase inhibitors (25mmol/L orthovanadate and 50 mmol/L NaF) (Sigma-Aldrich). The total protein concentration of the soluble extract was determined using the Bicinchoninic Acid Kit (Sigma-Aldrich).
Each protein sample (30 g) was resolved to SDS PAGE, transferred onto a polyvinylidene difluoride membrane (Millipore, Molsheim, μ -France) and incubated with a monoclonal antibody against III-tubulin (1 : 10 000; clone TUJ1; Covance, Emeryville, CA) or -actin (1 : β β 16 000; AC-15; Sigma-Aldrich). Primary antibodies against the other -tubulin isotypes were from Abcam (San Francisco, CA). Immune β complexes were visualised by enhanced chemiluminescence detection (ECL plus kit, GE Healthcare, Little Chalfont, UK).
cDNA synthesis and real-time PCR
Quantitative PCR was carried out using SYBR Green dye on an Applied Biosystems 7000 Real Time PCR system (Applied Biosystems, Foster City, CA, USA). The conditions for RT PCR have been described previously ( ). The amount of III-tubulin mRNA -25 β levels relative to the housekeeping gene Ribosomal Protein, large, P0 (RPLP0) was determined on the basis of the comparative threshold cycle CT method (2 ) . The primer sequences for III-tubulin and RPLP0 have been described previously ( , ) .
CT −Δ Δ β 25 26
Construction of bIII-tubulin expression vector and Generation of stable bIII-tubulin overexpressing cells
The ORF encoding bIII-tubulin was purchased from Invitrogen (Ultimate ORF clone, clone ID IOH3755, NM 00608.2). The bIII-tubulin ORF was provided in the Gateway entry vector pENTR 221. The bIII-tubulin expression was constructed by recombining the bIII-tubulin pENTR 221 into the destination vector pcDNA 3. silencing control siRNA, which has no sequence homology to any known human gene sequence, was used as a control for nonsequence-specific effects in all experiments.
Subconfluent human prostate cells were transfected with siRNA by using Lipofectamine 2000 (Invitrogen) following the manufacturer s instructions. 72 hours after the transfection, the efficacy of the siRNA knock down was assessed by qRT-PCR and by immunoblotting.
'
The optimal amount of siRNA used for transfection was determined as being 50 nmol/L and the best siRNA sequence allowing to reduce more than 70 of bIII-tubulin expression was identified as the sequence TUBB3HSS115887.
%
Docetaxel dose response curve
To assess the effect of III-tubulin overexpression on chemoresistance, 1x10 cells were seeded in 96-well microtiter plates. The next β 4 day, cells were treated with docetaxel at growing concentrations for 72 hours. Cell viability was determined by 3-4,5-dimethylthiazol-2-yl [ ] -2,5-diphenyl tetrazolium bromide (MTT) assay.
To assess the effect of the combination treatment of III-tubulin silencing plus docetaxel, 22Rv1 cells were transfected with 50 nM of β stealth siRNA against III-tubulin or control vector as described above and then treated with docetaxel at various concentrations for three β days. Cell viability was then determined by MTT assay.
The cell survival curve was presented as the percentage of surviving cells versus the concentration of docetaxel. The IC values were 50 defined as the concentration of drug required for 50 cell survival, and were calculated using a logarithmic regression. Results were % expressed as means SEM. Each assay was done in triplicate and was repeated on three separate experiments.
±
Patients and Tissue Samples
Written informed consent was obtained. The study included : Formalin-fixed, paraffin-embedded specimens were obtained from the Department of Pathology at the Henri Mondor Hospital, Cr teil, é France. Immunostaining was performed: (i) on the initial prostatic biopsies of 37 patients who had received first-line docetaxel-based chemotherapy; and ( ) on tissue microarrays (TMA) for the HNPC patient s cohort. When considering TMAs, for each PCa case, 4 7 ' replicate cores (diameter 0.6 mm) were obtained from cancer foci and four additional cores were also taken from nonneoplastic areas as previously described 25 .
[ ]
Immunohistochemistry (Supplementary Method)
Immunostaining was done on 5-m tissue sections mounted on silane-coated slides. III-tubulin protein expression was evaluated μ β using a monoclonal antibody specific for the III-tubulin isotype (1:500; clone TUJ1; Covance, Emeryville, CA). β A numerical score was assigned for the epithelial cells of each specimen. Samples with no stained tumour cells were scored as 0. A score of 1, 2, or 3 was assigned to samples with weak, moderate, or strong staining, respectively, independently of the proportion of stained tumour cells. The proportion of immunostained tumour cells was also assessed. For TMAs analysis, the mean of staining in the 4 neoplastic cores was considered. Only cytoplasmic staining was taken into account. All of the slides were independently evaluated by 3 observers (GP, ST, YA). Observers were blinded to the patients adjuvant treatment, final pathologic assessment, and outcome. Interrater 
Statistical analysis
Null expression (0 of stained cells) and weak to strong expression (score 1 to 3, and 5 of stained cells) were grouped separately as % ≥ % dichotomic variables for statistical analysis.
The Student-t test was used for continuous data. The Mann-Whitney test and the Kruskal-Wallis test were used when data were not normally distributed. Qualitative data were tested using a Chi-square test or Fisher s test as appropriate. The Gleason score was ' dichotomized according to the definition of high-risk prostate cancer as follows: Gleason score<8 versus 8 ( ). Survival curves were ≥ 2 generated by the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used to evaluate the independent value of III-tubulin expression among commonly used prognostic factors. Hazard ratios (HR) were presented with 95 β % CI.
(i) In the CRPC cohort, the starting point of the analysis was the first cycle of chemotherapy. The PSA Working Group criteria were used to evaluate PSA responses: we chose a decrease of >75 from the baseline PSA level as the criterion for PSA response ( ). The % 28 primary endpoint was overall survival (OS) defined as the time from the start of chemotherapy until death from any cause or last follow-up for censored patients. Time-to-progression was defined as the time between the first cycle of chemotherapy and an elevated PSA finding. (7) In the HNPC cohort, Biochemical RFS was analyzed. The day of surgery was reported as the starting point of analysis. Recurrence was defined as the first detectable elevation of PSA above 0.20 ng/ml (at least two consecutive measurements).
A value of p<0.05 was considered statistically significant, and all p values were two-sided. SPSS 13.0 (Chicago, Illinois) software was used for statistical analyses.
RESULTS
Prognostic value of III-tubulin expression for prostate cancer recurrence in hormone-na ve PCa patients treated by radical β ï prostatectomy
We had previously reported that III-tubulin was expressed significantly lower in hormone na ve PCa (HNPC) as compared to β ï castration resistant PCa (CRPC). In our previous study, however, the small patient sample size in the HNPC group (n 74) prevented us = from deriving any statistically reliable association with other patient prognostic factors ( ). Here, we extended our assessment of 21 β III-tubulin expression to PCa-containing specimens obtained from 258 PCa patients that were treated by radical prostatectomy ( ). Table 1 We identified III-tubulin expression in 43 of the 258 specimens from patients with HNPC (16.7 , ) . Strong III-tubulin β % Table 2 β immunostaining (score of 3.0) was detected in 6.2 of tumors. When III-tubulin expression was observed, the percentage of Table 2 found that positive immunostaining was significantly associated with a Gleason score 8 (p 0.001; OR 3.17), a primary Gleason grade of ≥ = 4 or 5 (p 0.013; OR 2.28), a pT stage 3 (p 0.042; OR 1.97), an extraprostatic extension (p 0.028; OR 2.10) and positive lymph nodes (p = ≥ = = 0.034; OR 3.05). It is noteworthy that III-tubulin expression was also significantly associated with a high risk for biochemical = β recurrence (p 0.029: OR 2.15). The intensity of immunostaining was also correlated with the histoprognostic parameters. A strong = immunostaining, defined by a staining score of 3 was also markedly associated with a Gleason score 8 (p<0.001), extraprostatic extension Increased expression of III-tubulin in prostate cancer cell lines in response to in vitro docetaxel treatment β We previously reported that III-tubulin expression was increased in LNCaP cells, ( ) that were grown in androgen depleted β 21 medium or in tumor xenografts from these cells after castration of the host mouse. In the present work, we tested whether docetaxel treatment could affect III-tubulin expression in two androgen-independent (AI) PCa cell lines; LNCaP-AI that expresses low levels of β β III-tubulin or 22Rv1 that endogenously expresses higher levels of III-tubulin. LNCaP-AI variant cells were treated with docetaxel at 3 β nmol/L for up to 30 days. As shown in , using Western blots to assess the levels of expressed III-tubulin protein, expression Figure 2A β was continuously elevated by exposure to docetaxel over the time course of the experiment. It is noteworthy that the class II -tubulin, an β isotype known to be predominantly expressed in the brain also increased along with total -tubulin under docetaxel exposure whereas no β Class III -tubulin and prostate cancer β Cancer Res . Author manuscript Page / 5 14 significant increase was seen for I and IV isotypes ( and ). To corroborate these findings, we set out to β β Fig. 2A  Supplementary Fig. S1 further characterize the expression of -tubulin isotypes in 22Rv1 under exposure to docetaxel at 15 nM for 72 hrs. The 22Rv1 PCa cell β line is derived from a primary tumor xenograft, CWR22, that relapsed during androgen ablation ( ). These cells express at least three 29 androgen receptor isoforms that appear to be constitutively active, likely promoting proliferation as well as the expression of multiple AR-dependent genes in a ligand-independent manner ( ). Consistent with earlier observations, upregulation of III-tubulin protein ( 23 β Fig.   and ) as well as mRNA levels ( ) was evident in docetaxel-treated 22Rv1 cells. 2B Supplementary Fig. S2A  Supplementary Fig. S2B The II-and total protein levels were similarly increased in docetaxel-treated cells in contrast to that found for I and IV isotypes.
Together, these data demonstrate that both acute and chronic exposure of AI prostate cancer cells to docetaxel upregulates III-tubulin β along with a seeming general increase of total -tubulin. overexpressing LNCaP cells had a neuroendocrine-like appearance ( ) suggesting that forced expression of Supplementary Fig. S3 β III-tubulin is associated with a trans-differentiation process that has been frequently described for these cells ( , ). To examine the 31 32 effects of III-tubulin over-expression, we measured the half-time inhibitory concentration (IC50) of docetaxel assessed by measuring cell β viability at 72 hrs after exposure. The cell viability assays showed that III-tubulin transfected LNCaP cells ( III-tubulin clone 1 and were again poorly sensitive to docetaxel when higher doses were tested ( Supplementary Fig. S4 ) Having established that III-tubulin has β severe implications for docetaxel resistance in LNCaP cells, we sought to determine if this could be due in part to an effect of III-tubulin β on cell proliferation. To this end, cell proliferation was assayed in the absence of drug. Cell doubling times for vector-transfected LNCaP and III-tubulin transfectants were estimated at 31h and 44h, respectively (supplementary Table 1 ). Two III-tubulin transfected DU145 β β clones were also selected for subsequent treatment including 1 clone expressing high levels of III-tubulin ( III-tubulin clone 7), and 1 β β clone expressing moderate III-tubulin ( III-tubulin clone 5) at a level similar to that found in parental or control vector-transfected DU β β 145 cells ( ). The cell viability assays showed that bIII-tubulin-transfected clone 7 was significantly more resistant to docetaxel Fig. 3A treatment compared to clone 5 or control vector-transfected DU 145 cells with a 2-fold increase in IC (11.1 versus 5.1 nmol/L, p<0.001, 50 ). A significant difference in cell viability between clone 7 and control cells was already achieved at 5 nmol/L (p<0.001). There Fig. 3B were no noticeable morphological differences between the parental vector-transfected DU145 and either of the two sublines. Nor were there any evident differences in growth rates noted during standard passage and cell proliferation assays of the sublines compared to the vector-transfected or parental cells (supplementary Table1).
βIII-tubulin silencing increases sensitivity to docetaxel
To further ascertain a role for III-tubulin in chemoresistance to docetaxel, siRNAs directed against III-tubulin was used to ). siRNA mediated loss of III-tubulin did not appear to affect the other III-tubulin isotypes (supplementary Figure S5 ). An By examining the III-tubulin status in the initial prostatic biopsies of patients subsequently treated for CRPC disease with docetaxel β chemotherapy, we investigated the usefulness of III-tubulin expression as a potential predictive tumor biomarker for response to β docetaxel. Of the 37 cases, 17 were positive for III-tubulin (9 with moderate and 8 with strong staining) whereas 20 were negative. ). Finally, baseline PSA levels measured prior to the first cycle of chemotherapy in these patients were also significantly related to OS. 4C
Multivariate analysis taking III-tubulin expression, baseline PSA, age, and duration of androgen deprivation therapy into account showed β that III-tubulin expression (HR 2.93; p 0.037) and baseline PSA level (HR 4.09; p 0.012) were independent predictors of OS.
DISCUSSION
In prostate cancer, clinical data and histoprognostic parameters, separated or integrated into nomograms still fail at the individual level to accurately determine the risk of biochemical or clinical relapse after local treatment ( , ). At CRPC stage, docetaxel-based 33 34 chemotherapy has proven to have some effectiveness in terms of overall response rates and survival in CRPC patients ( , ). However, 4 5 any selection of patients likely to benefit most from this form of chemotherapy is difficult and is often based simply upon patient age or the presence of co-morbidities in individuals.
Numerous preclinical studies have reported that the selective overexpression of III-tubulin constitutes an important mechanism for β resistance to tubulin-binding agents in various cancer cell lines ( , ) . Several clinical studies have shown that high levels of 19 35 -38 β III-tubulin expression in tumor cells are associated with low response rates and poorer survival in patients treated with taxane-based chemotherapies ( , ). Our findings in prostate cancer were consistent with the previous studies and highlight that the expression 13 -17 39 of III-tubulin is associated with non organ-confined disease, metastatic lymph nodes and PSA failure. Thus, tumor cell III-tubulin prostatectomy. The advent of PSA testing has lead to a considerable stage migration with an increase of low-risk prostate cancers. In our HNPC cohort study, we included patients who underwent radical prostatectomy since 1988. This constitutes a selection bias due a more important proportion of high-risk prostate cancer before the PSA era. These discrepancies may limit the study of III-tubulin expression as β the number of high-risk prostate cancers decreases over time. However, we showed that the prognostic impact of III-tubulin remained β significant in organ-confined PCa and therefore, we posit that the III-tubulin is of additional value to well-established histoprognostic β parameters even in the assessment of presumed low-risk PCa.
We also observed here that the III-tubulin expression in AI PCa cell lines was increased in response to acute or chronic exposure to β docetaxel. In line with our findings, Ranganathan et al. previously showed an increase in III-tubulin expression in response to paclitaxel β treatment of DU145 cells ( ). The exact mechanism by which increased expression of III-tubulin mediates drug resistance remains open 19 β to debate. In some instances, we found that alterations of III-tubulin expression were associated with changes in cell morphology and/or β cell proliferation rate. Thus, there is reason to believe that these events might be key determinants of drug resistance. Additionally, evidence is accumulating that microtubules containing III-tubulin exhibit an aberrant dynamicity. These microtubules are less stable than β microtubules composed of other -tubulin isotypes ( , , , ) Since the primary effect of taxane is to bind microtubules thereby β 9 10 40 41 enhancing the microtubule polymerization and decreasing microtubule dynamicity, it has been suggested that III-tubulin-containing β microtubules are more prone to overcome the suppressive effects of taxanes on microtubule dynamics. Although it should be noted that all the above studies ( , , ) have focused on the assembly of purified microtubules in cell free systems and therefore remain 12 13 43 controversial given contradictory reports obtained in intact cells, and hence more biologically relevant, that III-tubulin did not β intrinsically affect microtubule dynamic, at least in some instances ( , ) . Interestingly, in these last studies, the effects of paclitaxel on 38 42 microtubule dynamics were altered, suggesting a role for III-tubulin in drug-microtubule interactions. Consistent with this, Mozetti et al. cells ( ). In the setting of non-small cell lung cancer, III-tubulin was shown to impact significantly on the response to both tubulin 44 β targeting-agents and DNA-damaging agents ( ). The investigators proposed that III-tubulin may serve as a survival factor to rescue 45 β tumor cells from death signals triggered by chemotherapeutic agents. Therefore, it is conceivable that elevated expression of III-tubulin cancer cells ( , ), these cell lines differ from prostate cancer cells, and future work is warranted in order to determine the full 46 47 functional implications of each -tubulin isotype in the emergence of drug-resistance in prostate cancer cells. β Our findings in experimental prostate cancer cell lines were consistent with our clinical observations that III-tubulin expression in β prostate tumors correlated significantly with outcomes of docetaxel chemotherapy for CRPC patients. Patients expressing III-tubulin at β diagnosis had reduced survival. Thus it is tempting to speculate that the assessment of III-tubulin expression could determine which β CRPC patients might benefit from taxane-based chemotherapy. Studies exploring potential molecular markers in response to chemotherapy are currently limited by the difficulty in obtaining tissues from patients with CRPC. Many changes occurred during the evolution to CRPC, and cancer tissue at diagnosis does not always reflect accurately the cancer tissue in its more advanced stage. In fact, obtaining tumor tissue at CRPC stage, or before and during therapy, though rarely feasible in clinical practice, would certainly be the best way to investigate the impact of biomarker on response to therapy. Nevertheless, by examining III-tubulin expression in the tumors of β HNPC patients, which are easily accessible to tumor sampling, it seems possible to evaluate their response to docetaxel-based therapy once the disease has progressed to CRPC. If these findings are confirmed, the use of novel tubulin-targeted agents, such as epothilones, could be useful for III-tubulin-positive PCa patients ( , , ) . This might also offer the opportunity for therapeutic intervention by an anti- Collectively, our results suggest that the functional and clinical biomarker aspects of III-tubulin expression are linked. Consistent β with our previous findings and other studies reporting an increase in the III-tubulin isotype as a result of anti-microtubule drug treatments β ( , , ), it seems likely that adjuvant treatments other than the current taxane-based chemotherapy regimen may be required for this 19 20 50 group of patients. More importantly, our results now support the idea that III-tubulin expression may be linked to multiple forms of PCa; β progression to recurrence in HNPC patients, progression to CRPC in hormone-treated patients and, finally, progression to docetaxel resistance in docetaxel-treated CRPC patients. In the area of cancer treatment, clinicians have to deal with two limitations: the difficulty to predict accurately the relapse after local treatment; and the ability to anticipate ineffective adjuvant or systemic therapy. To date, in prostate cancer, new molecular markers are needed to better define the subset of patients who are most likely to benefit from an adjuvant strategy after radical treatment, and from chemotherapy at CRPC stage. Our findings were consistent with the role of III-tubulin β expression as prognostic marker of biochemical recurrence at HNPC stage. Assessment of the III-tubulin expression in cancer tissue β therefore could be useful to identify and monitor prostate cancer at high risk for recurrence after radical prostatectomy. If longer follow-up and rates of specific mortality confirm these results, the III-tubulin expression might be interesting for predicting recurrence rates and for Recurrence-free survival (RFS) curves stratified by the expression of III-tubulin (negativity versus positivity of immunostaining, log-rank β test; p 0.002). HNPC: hormone naive prostate cancer; TMA: tissue micro-array. 
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